Category: Hepatitis C

CATIE’s HepCInfo Update 5.6

New and Noteworthy In this issue of HepCinfo Update, we cover selected results from four clinical trials of Hep C medication combinations presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014). These trials are noteworthy for a number of reasons: The cure rates in all of these trials are very high (85-99%)…. Read more »

Hepatitis C virus (HCV) can infect the liver, causing inflammation that injures this organ. If HCV is left untreated, injury can spread throughout the liver and this organ consequently becomes increasingly dysfunctional. As a result, the eventual appearance of serious symptoms related to liver damage occurs and a person’s quality of life degrades. HCV infection… Read more »

Update on PHAC’s HIV and Hepatitis C Activities

Under the Federal Initiative to Address HIV/AIDS in Canada and the Hepatitis C Prevention, Support and Research Program, the Agency currently manages separate funding programs to support the community response to HIV and hepatitis C. The projects under these programs are in the process of being extended for three years, from April 1, 2014 –… Read more »

CATIE HepCinfo Update 5.5

6 week treatment cures almost all “hard to treat” participants A six-week treatment of sofosbuvir (Sovaldi), ledipasvir and a third drug cured a majority of people with genotype 1 Hep C virus who had never been treated before, according to research presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) in Boston…. Read more »

CATIE’s HepCInfo Update 5.4

New and Noteworthy European Medicines Agency advises on compassionate use of sofosbuvir (Sovaldi) and ledipasvir The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the compassionate use of sofosbuvir (Sovaldi) and ledipasvir for people with hepatitis C who are at high risk of liver failure or death within 12 months…. Read more »

Spring update from PHCN

This last month has been a whirlwind of symposiums, conferences and meetings.  We learned and shared a lot during our time spent with colleagues and collaborators across the country.  At the PAN ‘Effective Interventions’ conference in Vancouver, we presented on the benefits of the Community Readiness Model.   In Toronto, we presented about the patient experience… Read more »

CATIE’s HepCInfo Update 5.1

New and Noteworthy Montreal study shows testing positive for hepatitis C linked to decreased injection drug use People who inject drugs and who test positive for hepatitis C were more likely to decrease their drug use then people who tested negative, reported researchers in Clinical Infectious Diseases. From 2004 to 2011, the University of Montreal… Read more »

From CATIE: Top 10 HIV and Hep C Research News from 2013

Original posted on CATIE. Top 10 HIV and Hep C Research News from 2013 What were the most notable HIV and hepatitis C research stories from 2013? We’ve listed the top 10 stories from CATIE News below.   1. New evidence-based approaches to HIV and hepatitis C From national guidelines for HIV testing to best… Read more »